Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gamifying exercise: could a phone app outperform traditional programs for obesity and diabetes?

NCT ID NCT04887077

Disease control Sponsor: University Hospital, Clermont-Ferrand Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time

Summary

This trial tests whether a smartphone app called Kiplin, which uses games, telecoaching, and social support, can increase daily physical activity in people with obesity or type 2 diabetes. It compares the app to a standard three-month face-to-face exercise program. The main goal is to see if the app leads to a greater increase in daily step count after three months, with follow-up at nine months to check lasting effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A smartphone app called Kiplin that gamifies physical activity with games, telecoaching, social features, and activity tracking
What this could lead to
If effective, this digital approach could offer a scalable, engaging way to help people with obesity or type 2 diabetes become more active and improve health outcomes.
What could go wrong
The trial is small (56 participants) and early, so results may not apply broadly. The app's success depends on user engagement, which can wane over time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

56 people

The number who actually took part.

Started

Jun 2021

Finished

Oct 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subject affected for obesity (BMI ≥30 kg/m² and \<45 kg/m²) and/or T2DM. * Subject treated at the University Hospital of Clermont-Ferrand. * The participants must have an iOS (at least iOS8 version) or Android (at least version 5) smartphone. * Subjects must also be able to provide informed consent to participate in the research and be covered by health social security. * Subjects must be native to any physical activity intervention. * Sufficient proficiency of French will be required to ensure the understanding of the questionnaires. Exclusion Criteria: * Medical or surgical history judged by the investigator to be incompatible with the study. * Subject with an unstable psychiatric condition. * Pregnant or breastfeeding women. * Heavy alcohol consumption (\> 2 to 3 drinks per day depending on gender) or drug addiction. * Disability or contraindication to PA. * Subject with cardiorespiratory and/or osteoarticular disorders that limit their ability to perform physical tests or moderate PA for 30 minutes. * Subject with progressive cardiovascular or neoplastic disease. * Subject who has presented a major infection in the 3 months prior to inclusion. * Subject with a known neuro-muscular pathology (i.e., myopathy, myasthenia, rhabdomyolysis, paraplegia, hemiplegia). * Subject with chronic or acute inflammatory pathology within 3 months prior to inclusion. * Subject diagnosed and/or treated for schizophrenia, bipolar disorder, major depression. * Subject deprived of their liberty by judicial or administrative decision. * Subject refusing to sign the written consent to participate. * Subject participating in another study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabete type 2 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Motor Activity Obesity obesity disorder type 2 diabetes mellitus Weight Prejudice

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabete type 2 Obesity

Contacts and locations

Locations

  • CHU de Clermont-Ferrand

    Clermont-Ferrand, 63000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.